Immunogenicity and Reactogenicity of Ad26.COV2.S in Korean Adults: A Prospective Cohort Study

被引:1
|
作者
Hyun, Hakjun [1 ]
Choi, Min Joo [4 ,7 ]
Heo, Jung Yeon [5 ]
Seo, Yu Bin [6 ]
Nham, Eliel [1 ]
Yoon, Jin Gu [1 ]
Seong, Hye [1 ]
Noh, Ji Yun [1 ,2 ,3 ]
Cheong, Hee Jin [1 ]
Kim, Woo Joo [1 ,2 ,3 ]
Choi, Ju-Yeon
Lee, Young Jae
Lee, Hye Won
Kim, Sung Soon
Kim, Byoungguk
Song, Joon Young [1 ,2 ,3 ]
机构
[1] Korea Univ, Dept Internal Med, Div Infect Dis, Coll Med, Seoul, South Korea
[2] Korea Univ, Asia Pacific Influenza Inst, Coll Med, Seoul, South Korea
[3] Vaccine Innovat Ctr KU Med VIC K, Seoul, South Korea
[4] Catholic Kwandong Univ, Dept Internal Med, Int St Marys Hosp, Coll Med, Incheon, South Korea
[5] Ajou Univ, Dept Infect Dis, Sch Med, Suwon, South Korea
[6] Hallym Univ, Kangnam Sacred Heart Hosp, Dept Internal Med, Div Infect Dis,Coll Med, Seoul, South Korea
[7] Natl Inst Infect Dis, Ctr Vaccine Res, Div Vaccine Clin Res, Cheongju, South Korea
关键词
SARS-CoV-2; COVID-19; Vaccines; Adenovirus Vector; Humoral Immunity; Cellular Immunity; Adverse Events;
D O I
10.3346/jkms.2022.37.e210
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: As the coronavirus disease 2019 (COVID-19) pandemic continues, there are concerns regarding waning immunity and the emergence of viral variants. The immunogenicity of Ad26.COV2.S against wild-type (WT) and variants of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) needs to be evaluated. Method: This prospective cohort study was conducted between June 2021 and January 2022 at two university hospitals in South Korea. Healthy adults who were scheduled to be vaccinated with Ad26.COV2.S were enrolled in this study. The main outcomes included anti-spike (S) IgG antibody and neutralizing antibody responses, S-specific T-cell responses (interferon-. enzyme-linked immunospot assay), solicited adverse events (AEs), and serious AEs. Results: Fifty participants aged >= 19 years were included in the study. Geometric mean titers (GMTs) of anti-S IgG were 0.4 U/mL at baseline, 5.2 +/- 3.0 U/mL at 3-4 weeks, 55.7 +/- 2.4 U/mL at 5-8 weeks, and 81.3 +/- 2.5 U/mL at 10-12 weeks after vaccination. GMTs of 50% neutralizing dilution (ND50) against WT SARS- CoV-2 were 164.6 +/- 4.6 at 3-4 weeks, 313.9 +/- 3.6 at 5-8 weeks, and 124.4 +/- 2.6 at 10-12 weeks after vaccination. As for the S-specific T-cell responses, the median number of spot-forming units/106 peripheral blood mononuclear cell was 25.0 (5.0-29.2) at baseline, 60.0 (23.3-178.3) at 5-8 weeks, and 35.0 (13.3-71.7) at 10-12 weeks after vaccination. Compared to WT SARS-CoV-2, ND50 against Delta and Omicron variants was attenuated by 3.6-fold and 8.2-fold, respectively. The most frequent AE was injection site pain (82%), followed by myalgia (80%), fatigue (70%), and fever (50%). Most AEs were grade 1-2, and resolved within two days. Conclusion: Single-dose Ad26.COV2.S was safe and immunogenic. NAb titer and S-specific T-cell immunity peak at 5-8 weeks and rather decrease at 10-12 weeks after vaccination. Cross-reactive neutralizing activity against the Omicron variant was negligible.
引用
收藏
页数:9
相关论文
共 50 条
  • [41] Anti-SARS-CoV-2 IgG against the S Protein: A Comparison of BNT162b2, mRNA-1273, ChAdOx1 nCoV-2019 and Ad26.COV2.S Vaccines
    Szczepanek, Joanna
    Skorupa, Monika
    Goroncy, Agnieszka
    Jarkiewicz-Tretyn, Joanna
    Wypych, Aleksandra
    Sandomierz, Dorota
    Jarkiewicz-Tretyn, Aleksander
    Dejewska, Joanna
    Ciechanowska, Karolina
    Palgan, Krzysztof
    Rajewski, Pawel
    Tretyn, Andrzej
    VACCINES, 2022, 10 (01)
  • [42] Comparison of antibody response durability of mRNA-1273, BNT162b2, and Ad26.COV2.S SARS-CoV-2 vaccines in healthcare workers
    Brunner, Wendy M.
    Freilich, Daniel
    Victory, Jennifer
    Krupa, Nicole
    Scribani, Melissa B.
    Jenkins, Paul
    Lasher, Emily G.
    Fink, Amanda
    Shah, Anshini
    Cross, Peggy
    Bush, Valerie
    Peek, Laura J.
    Pestano, Gary A.
    Gadomski, Anne M.
    INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2022, 123 : 183 - 191
  • [43] Humoral and Cellular Immunogenicity of Six Different Vaccines against SARS-CoV-2 in Adults: A Comparative Study in Tunisia (North Africa)
    Ben Ahmed, Melika
    Bellali, Hedia
    Gdoura, Mariem
    Zamali, Imen
    Kallala, Ouafa
    Ben Hmid, Ahlem
    Hamdi, Walid
    Ayari, Hela
    Fares, Hajer
    Mechri, Karim
    Marzouki, Soumaya
    Triki, Henda
    Ben Alaya, Nissaf
    Chahed, Mohamed Kouni
    Klouz, Anis
    Sebai Ben Amor, Sonia
    Ben Rayana, Chiheb
    Razgallah Khrouf, Myriam
    Hamouda, Chokri
    Elkadri, Noomene
    Daghfous, Riadh
    Trabelsi, Abdelhalim
    VACCINES, 2022, 10 (08)
  • [44] Fatal vaccine-induced immune thrombotic thrombocytopenia (VITT) post Ad26.COV2.S: first documented case outside US
    Elsa V. C. Rodriguez
    Fatima-Zohra Bouazza
    Nicolas Dauby
    François Mullier
    Stéphanie d’Otreppe
    Patrice Jissendi Tchofo
    Magali Bartiaux
    Camille Sirjacques
    Alain Roman
    Cédric Hermans
    Manuel Cliquennois
    Infection, 2022, 50 : 531 - 536
  • [45] Vaccine-induced immune thrombotic thrombocytopenia in a male after Ad26.COV2.S vaccination presenting as cerebral venous sinus thrombosis
    Wu, James Fan
    Bajwa, Umair
    Hammad, Muhammad
    PLATELETS, 2022, 33 (05) : 797 - 800
  • [46] Review Temporal Association Between the COVID-19 Ad26.COV2.S Vaccine and Acute Myocarditis: A Case Report and Literature Review
    Sulemankhil, Imran
    Abdelrahman, Mohammad
    Negi, Smita I.
    CARDIOVASCULAR REVASCULARIZATION MEDICINE, 2022, 38 : 117 - 123
  • [47] Fatal vaccine-induced immune thrombotic thrombocytopenia (VITT) post Ad26.COV2.S: first documented case outside US
    Rodriguez, Elsa V. C.
    Bouazza, Fatima-Zohra
    Dauby, Nicolas
    Mullier, Francois
    d'Otreppe, Stephanie
    Jissendi Tchofo, Patrice
    Bartiaux, Magali
    Sirjacques, Camille
    Roman, Alain
    Hermans, Cedric
    Cliquennois, Manuel
    INFECTION, 2022, 50 (02) : 531 - 536
  • [48] Heterologous Ad26.COV2.S Prime and mRNA-Based Boost COVID-19 Vaccination Regimens: The SWITCH Trial Protocol
    Sablerolles, Roos S. G.
    Goorhuis, Abraham
    GeurtsvanKessel, Corine H.
    de Vries, Rory D.
    Huckriede, Anke L. W.
    Koopmans, Marion P. G.
    Lafeber, Melvin
    Postma, Douwe F.
    van Baarle, Debbie
    Visser, Leo G.
    Dalm, Virgil A. S. H.
    Kootstra, Neeltje A.
    Rietdijk, Wim J. R.
    van der Kuy, P. Hugo M.
    FRONTIERS IN IMMUNOLOGY, 2021, 12
  • [49] A case report of vaccine-induced immune thrombocytopenia and thrombosis syndrome after Ad26.COV2.S vaccine (Janssen/Johnson & Johnson)
    Castan, Maxime
    Damin-Pernik, Marlene
    Thiery, Guillaume
    Page, Dominique
    Smadja, David M.
    Bertoletti, Laurent
    THERAPIE, 2022, 77 (06): : 734 - 737
  • [50] The Biodistribution of the Spike Protein after Ad26.COV2.S Vaccination Is Unlikely to Play a Role in Vaccine-Induced Immune Thrombotic Thrombocytopenia
    Marquez-Martinez, Sonia
    Khan, Selina
    Lubbe, Joan van der
    Solforosi, Laura
    Costes, Lea M. M.
    Choi, Ying
    Boedhoe, Satish
    Verslegers, Mieke
    Heerden, Marjolein van
    Roosen, Wendy
    Jonghe, Sandra De
    Kristyanto, Hendy
    Rezelj, Veronica
    Hendriks, Jenny
    Serroyen, Jan
    Tolboom, Jeroen
    Wegmann, Frank
    Zahn, Roland C.
    VACCINES, 2024, 12 (05)